Ewa Chmielowska

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

Michael Wang, Simon Rule, Peter Martin et al. · New England Journal of Medicine · 2013 · 1.7K citations · Full text

Medicine, Hematology, Pharmacology +17

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

Cathy Eng, Tae Won Kim, Johanna C. Bendell et al. · The Lancet Oncology · 2019 · 562 citations · Full text

Medicine, Oncology, Pharmacology +11

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

Michael Wang, Kristie A. Blum, Peter Martin et al. · Blood · 2015 · 402 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Postibrutinib outcomes in patients with mantle cell lymphoma

Peter Martin, Kami J. Maddocks, John P. Leonard et al. · Blood · 2016 · 283 citations · Full text

Medicine, Hematology, Oncology +8